格隆汇12月15日丨锦欣生殖(01951.HK)公告，12月15日耗资993.9万港元回购389.1万股。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 錦欣生殖醫療集團有限公司 呈交日期： 2025年12月15日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 01951 | 說明 | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | 已發行股份（ ...

Group 1 - The stock price of Jinxin Reproductive Medicine (01951) increased by 1.99% to HKD 2.56, with a trading volume of HKD 66.02 million [2][5] - The National Medical Security Work Conference held on December 13 emphasized the need to adapt to population development strategies and promote the development of maternity insurance and long-term care insurance [2][5] - By 2025, all 31 provinces and regions, including Xinjiang Production and Construction Corps, are expected to include eligible assisted reproductive projects in medical insurance, with 7 provinces achieving full coverage of hospitalization costs for childbirth [2][5] Group 2 - Jinxin Reproductive Medicine announced a share buyback plan with a total price of no less than HKD 100 million, having repurchased 23.224 million shares for HKD 57.717 million last week [2][5] - As of now, the company has completed the buyback of 30.946 million shares this month, totaling HKD 77.515 million [2][5] - The company aims to focus on improving operational performance and enhancing intrinsic value to create sustainable returns for shareholders [2][5]

Core Viewpoint - The Hong Kong stock market saw a rise in three-child policy concept stocks, driven by a recent national medical insurance conference that outlined plans to enhance maternity insurance and support for various employment groups [1] Group 1: Policy Impact - The national medical insurance conference emphasized the need to adapt to population development strategies by promoting maternity insurance and long-term care insurance by 2026 [1] - The policy aims to include flexible workers, migrant workers, and new employment forms in maternity insurance coverage [1] - There is a goal to improve the medical expense coverage for prenatal checks, aiming for "no out-of-pocket" expenses for childbirth within the policy scope nationwide [1] Group 2: Market Reaction - Stocks related to assisted reproduction and maternal and child healthcare sectors reacted positively, with companies like Jinxin Fertility rising approximately 4% [1] - Other companies such as China Feihe, Mengniu Dairy, and China Wangwang also experienced gains of 2%, 1.4%, and 0.21% respectively [2]

本文源自：金融界AI电报 港股三胎概念股逆势上涨，锦欣生殖盘初涨约4%，中国飞鹤涨2%，蒙牛乳业涨1.4%，中国旺旺跟涨。 ...

Group 1 - The core viewpoint of the news is that Hong Kong stocks related to the three-child policy are experiencing an upward trend, driven by recent government policies aimed at enhancing fertility insurance and maternal healthcare [1] - The national medical insurance work conference held in Beijing emphasized the need to adapt to population development strategies by promoting the development of maternity insurance and long-term care insurance [1] - The policy aims to include flexible workers, migrant workers, and new employment forms in the coverage of maternity insurance, and to improve the medical expense coverage for prenatal checks, striving for "no out-of-pocket" expenses for childbirth within the policy scope [1] Group 2 - Analysts suggest that the new policy will directly benefit sectors such as assisted reproduction and obstetrics, while also providing sustained advantages to the maternal and infant consumption industry chain, including retail, food, and supplies [1] - Stocks of companies like Jinxin Fertility (up approximately 4%), China Feihe (up 2%), Mengniu Dairy (up 1.4%), and China Wangwang (up 0.21%) have reacted positively to the policy announcement [1][2] - Jinxin Fertility is highlighted as a leading player in the assisted reproduction sector in Hong Kong, indicating strong market confidence in the company's prospects following the policy changes [1]

Core Viewpoint - The stock of Jinxin Fertility (01951) has increased by over 3%, currently trading at 2.6 HKD with a transaction volume of 45.4 million HKD, following the announcement of supportive policies for reproductive health insurance in China [1] Group 1: Industry Developments - The National Medical Security Work Conference held on December 13 in Beijing emphasized the need to adapt to population development strategies and promote the growth of maternity insurance and long-term care insurance [1] - The conference aims for nationwide basic realization of "no out-of-pocket" expenses for childbirth within the policy scope, with a target for 2025 that all 31 provinces (regions, municipalities) and the Xinjiang Production and Construction Corps will include eligible assisted reproductive projects in medical insurance [1] - Seven provinces are expected to achieve full coverage of hospitalization expenses for childbirth within the policy scope, and 95% of coordinated areas will directly distribute maternity allowances to insured individuals [1] Group 2: Company Actions - Jinxin Fertility announced a decision by its board to utilize buyback authorization to repurchase shares in the open market for a total price of no less than 100 million HKD [1] - Last week, the company repurchased 23.2 million shares at a cost of 57.7 million HKD, and as of now, it has completed the buyback of 30.9 million shares this month, totaling 77.5 million HKD [1] - The company stated its commitment to focus on improving operational performance and driving intrinsic value growth to create sustainable returns for shareholders [1]

Core Viewpoint - The stock of Jinxin Fertility (01951) has risen over 3%, currently trading at 2.6 HKD, with a transaction volume of 45.4 million HKD, following the announcement of supportive policies for fertility and long-term care insurance in China [1] Group 1: Industry Developments - The National Medical Security Work Conference held on December 13 in Beijing emphasized adapting to population development strategies and promoting the development of maternity insurance and long-term care insurance [1] - The conference aims to reasonably enhance the medical expense coverage for prenatal examinations, striving for nationwide "no out-of-pocket" expenses for childbirth within the policy scope [1] - By 2025, all 31 provinces (regions, municipalities) and the Xinjiang Production and Construction Corps are expected to include eligible assisted reproductive projects in medical insurance, with 7 provinces achieving full coverage of hospitalization expenses for childbirth within the policy scope [1] - 95% of the coordinated areas will directly distribute maternity allowances to insured individuals [1] Group 2: Company Actions - Jinxin Fertility announced a decision by its board to utilize buyback authorization to repurchase shares in the open market for a total price of no less than 100 million HKD [1] - Last week, the company repurchased 23.2 million shares at a cost of 57.7 million HKD [1] - As of now, the company has completed the repurchase of 30.9 million shares this month, totaling 77.5 million HKD, and it plans to continue focusing on improving operational performance and enhancing intrinsic value for sustainable shareholder returns [1]

消息面上，12月13日，全国医疗保障工作会议在北京召开。会上提到，要积极适应人口发展战略，推动 生育保险和长期护理保险发展。其中包括，合理提升产前检查医疗费用保障水平，力争全国基本实现政 策范围内分娩个人"无自付"。会议提出，2025年，31个省（区、市）及新疆生产建设兵团均已将符合条 件的辅助生殖项目纳入医保，7个省份实现政策范围内住院分娩医疗费用全额保障，95%的统筹区将生 育津贴直接发放给参保人。 智通财经APP获悉，锦欣生殖(01951)涨超3%，截至发稿，涨3.59%，报2.6港元，成交额4539.81万港 元。 本月初，锦欣生殖发布公告称，董事会已议决利用购回授权，以不时在公开市场上按不少于1亿港元的 总价格购回股份。据锦欣生殖投资者关系消息，上周公司回购股份2322.4万股，耗资5771.7万港币。截 止目前，本月已完成回购3094.6万股，总金额7751.5万港币。公司表示未来将继续专注提升经营业绩， 推动公司内在价值增长，致力为股东创造可持续的回报。 ...

恐慌情绪蔓延！上周五美股大跌；今日将公布社零等重磅经济数据。港股三大指数大幅低开，恒指跌 1%，国指跌1.09%，恒生科技指数跌1.34%。权重科技股集体下跌，其中百度跌超3%，阿里巴巴、腾 讯、小米均有跌幅；内房股、生物医药股、有色金属股齐跌。另外，三胎概念股、光伏股多数上涨，明 星股锦欣生殖涨约3%。(格隆汇) ...